CY1123337T1 - Ειδικα σχεδιασμενα λιποσωματα για τη θεραπεια βακτηριακων μολυνσεων - Google Patents
Ειδικα σχεδιασμενα λιποσωματα για τη θεραπεια βακτηριακων μολυνσεωνInfo
- Publication number
- CY1123337T1 CY1123337T1 CY20201100878T CY201100878T CY1123337T1 CY 1123337 T1 CY1123337 T1 CY 1123337T1 CY 20201100878 T CY20201100878 T CY 20201100878T CY 201100878 T CY201100878 T CY 201100878T CY 1123337 T1 CY1123337 T1 CY 1123337T1
- Authority
- CY
- Cyprus
- Prior art keywords
- liposomes
- treatment
- liposomes containing
- sphingomyelin
- lipid composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
Η εφεύρεση σχετίζεται με τη χρήση κενών λιποσωμάτων καθορισμένης λιπιδικής σύνθεσης ή μιγμάτων κενών λιποσωμάτων καθορισμένης λιπιδικής σύνθεσης και με τη χρήση άλλων λιπιδικών διπλοστιβάδων ή μονοστιβάδων καθορισμένης λιπιδικής σύνθεσης για τη θεραπεία και την πρόληψη βακτηριακών μολύνσεων. Έχει βρεθεί ότι τέτοια λιποσώματα, ιδιαίτερα ένα μίγμα δύο και τεσσάρων συστατικών λιποσωμάτων που περιέχουν χοληστερόλη και σφιγγομυελίνη, λιποσωμάτων που περιέχουν σφιγγομυελίνη, λιποσωμάτων που περιέχουν σφιγγομυελίνη και φωσφατιδυλοχολίνη, και λιποσωμάτων που περιέχουν χοληστερόλη και φωσφατιδυλοχολίνη παγιδεύουν αποτελεσματικά μια ποικιλία τοξινών που εκκρίνονται από βακτήρια, εμποδίζοντας έτσι τη σύνδεση βακτηριακών τοξινών σε στοχευόμενα κύτταρα και την προκαλούμενη από τοξίνες λύση των στοχευόμενων κυττάρων. Όταν ενέθηκαν ενδοφλέβια, τα μίγματα λιποσωμάτων εμπόδισαν το θάνατο εργαστηριακών ποντικών που είχαν μολυνθεί με θανατηφόρες δόσεις Staphylococcus aureus ή Streptococcus pneumonia.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12171924 | 2012-06-14 | ||
EP13153039 | 2013-01-29 | ||
EP13732388.7A EP2861214B1 (en) | 2012-06-14 | 2013-06-13 | Tailored liposomes for the treatment of bacterial infections |
PCT/EP2013/062207 WO2013186286A1 (en) | 2012-06-14 | 2013-06-13 | Tailored liposomes for the treatment of bacterial infections |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123337T1 true CY1123337T1 (el) | 2021-12-31 |
Family
ID=48703423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100878T CY1123337T1 (el) | 2012-06-14 | 2020-09-16 | Ειδικα σχεδιασμενα λιποσωματα για τη θεραπεια βακτηριακων μολυνσεων |
Country Status (19)
Country | Link |
---|---|
US (4) | US10744089B2 (el) |
EP (2) | EP2861214B1 (el) |
JP (2) | JP6382801B2 (el) |
CN (2) | CN104602672B (el) |
AU (2) | AU2013276565B2 (el) |
BR (1) | BR112014031278B1 (el) |
CA (1) | CA2875470C (el) |
CY (1) | CY1123337T1 (el) |
DK (1) | DK2861214T3 (el) |
ES (1) | ES2821502T3 (el) |
HK (1) | HK1210018A1 (el) |
HR (1) | HRP20201761T1 (el) |
HU (1) | HUE051761T2 (el) |
LT (1) | LT2861214T (el) |
PL (1) | PL2861214T3 (el) |
RS (1) | RS60951B1 (el) |
RU (1) | RU2672106C2 (el) |
SI (1) | SI2861214T1 (el) |
WO (1) | WO2013186286A1 (el) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS60951B1 (sr) * | 2012-06-14 | 2020-11-30 | Univ Bern | Lipozomi prilagođeni za lečenje bakterijskih infekcija |
WO2015084677A1 (en) | 2013-12-02 | 2015-06-11 | Arytha Biosciences, Llc | Toxoid preparation and uses thereof |
US10739353B2 (en) * | 2014-12-31 | 2020-08-11 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
US20200281950A1 (en) | 2015-12-28 | 2020-09-10 | Mb Biotech Ltd. | Liposomes for treatment of an autoimmune disease |
WO2017177073A1 (en) * | 2016-04-07 | 2017-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use |
PT3471732T (pt) | 2016-06-16 | 2020-08-24 | Combioxin Sa | Lipossomas para o tratamento de infeções virais |
CN116549393A (zh) | 2017-03-02 | 2023-08-08 | 康柏辛股份有限公司 | 抑制生物膜形成的脂质体 |
US11344497B1 (en) * | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
PT3781172T (pt) * | 2018-04-17 | 2023-10-11 | Combioxin Sa | Tratamento da pneumonia |
CA3097045A1 (en) * | 2018-04-20 | 2019-10-24 | Samareh Azeredo Da Silveira Lajaunias | Treatment of sepsis and septic shock |
CN111214439B (zh) * | 2018-11-23 | 2023-02-10 | 复旦大学 | 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途 |
EP4188398A1 (en) * | 2020-07-31 | 2023-06-07 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
CN115054577A (zh) * | 2022-05-17 | 2022-09-16 | 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) | 纳米解毒剂及其在中和mrsa穿孔毒素的应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004019A1 (en) * | 1989-09-12 | 1991-04-04 | The Regents Of The University Of California | Therapeutic peptides and proteins |
NL9000207A (el) * | 1990-01-29 | 1991-08-16 | Duphar Int Res | |
AU2583892A (en) * | 1991-09-11 | 1993-04-05 | Pitman-Moore, Inc. | Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides |
US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5741516A (en) * | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US6726925B1 (en) * | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
US8110217B2 (en) * | 2001-08-13 | 2012-02-07 | University Of Pittsburgh | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders |
ES2387886T3 (es) * | 2001-11-13 | 2012-10-03 | Celator Pharmaceuticals, Inc. | Composiciones que transportan lípidos con una mejor estabilidad sanguínea |
CA2368656A1 (en) * | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Receptor-ligand pairing for anti-inflammatory response |
WO2003099217A2 (en) * | 2002-05-23 | 2003-12-04 | Activbiotics, Inc. | Methods of treating bacterial infections and diseases associated therewith |
WO2004047800A2 (en) * | 2002-11-26 | 2004-06-10 | Gilead Sciences, Inc. | Method of drug loading in liposomes by gradient |
EP1610763A2 (en) * | 2003-03-31 | 2006-01-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Stable liposomes or micelles comprising a sphingolipid and a peg-lipopolymer |
JP4990786B2 (ja) | 2004-11-05 | 2012-08-01 | イネックス ファーマシューティカルズ コーポレイション | 薬物リポソーム製剤を安定化するための組成物および方法 |
CN1939340A (zh) * | 2005-09-29 | 2007-04-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 脂质体制剂 |
US20080131497A1 (en) * | 2006-09-28 | 2008-06-05 | Perkins Walter R | Formulations of DNase and Methods of Use Thereof |
CA2669355C (en) * | 2006-11-06 | 2012-10-30 | Jina Pharmaceuticals, Inc. | Guggulphospholipid methods and compositions |
CN1994279A (zh) * | 2006-12-31 | 2007-07-11 | 西安力邦医药科技有限责任公司 | 注射用盐酸伊立替康脂质体的制备方法 |
CN101623262B (zh) * | 2009-08-24 | 2011-02-02 | 海南美大制药有限公司 | 一种五水头孢唑啉钠前体脂质体制剂 |
SG187770A1 (en) * | 2010-08-12 | 2013-03-28 | Univ Nanyang Tech | A liposomal formulation for ocular drug delivery |
CN102327220B (zh) * | 2011-07-14 | 2012-09-26 | 海南灵康制药有限公司 | 一种氯雷他定脂质体固体制剂 |
RS60951B1 (sr) * | 2012-06-14 | 2020-11-30 | Univ Bern | Lipozomi prilagođeni za lečenje bakterijskih infekcija |
-
2013
- 2013-06-13 RS RS20201252A patent/RS60951B1/sr unknown
- 2013-06-13 JP JP2015516609A patent/JP6382801B2/ja active Active
- 2013-06-13 DK DK13732388.7T patent/DK2861214T3/da active
- 2013-06-13 SI SI201331806T patent/SI2861214T1/sl unknown
- 2013-06-13 EP EP13732388.7A patent/EP2861214B1/en active Active
- 2013-06-13 US US14/404,985 patent/US10744089B2/en active Active
- 2013-06-13 RU RU2014148284A patent/RU2672106C2/ru active
- 2013-06-13 CA CA2875470A patent/CA2875470C/en active Active
- 2013-06-13 LT LTEP13732388.7T patent/LT2861214T/lt unknown
- 2013-06-13 HU HUE13732388A patent/HUE051761T2/hu unknown
- 2013-06-13 CN CN201380031384.7A patent/CN104602672B/zh active Active
- 2013-06-13 PL PL13732388T patent/PL2861214T3/pl unknown
- 2013-06-13 BR BR112014031278-8A patent/BR112014031278B1/pt active IP Right Grant
- 2013-06-13 AU AU2013276565A patent/AU2013276565B2/en active Active
- 2013-06-13 ES ES13732388T patent/ES2821502T3/es active Active
- 2013-06-13 EP EP20189368.2A patent/EP3782606A1/en active Pending
- 2013-06-13 CN CN201811433069.8A patent/CN109549925B/zh active Active
- 2013-06-13 WO PCT/EP2013/062207 patent/WO2013186286A1/en active Application Filing
-
2015
- 2015-10-30 HK HK15110746.9A patent/HK1210018A1/xx unknown
-
2018
- 2018-08-02 JP JP2018145681A patent/JP6656321B2/ja active Active
-
2019
- 2019-03-14 AU AU2019201776A patent/AU2019201776B2/en active Active
-
2020
- 2020-07-09 US US16/924,539 patent/US20200345639A1/en not_active Abandoned
- 2020-09-16 CY CY20201100878T patent/CY1123337T1/el unknown
- 2020-10-30 HR HRP20201761TT patent/HRP20201761T1/hr unknown
-
2021
- 2021-11-30 US US17/537,862 patent/US20220087934A1/en not_active Abandoned
-
2022
- 2022-09-30 US US17/957,402 patent/US20230031648A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123337T1 (el) | Ειδικα σχεδιασμενα λιποσωματα για τη θεραπεια βακτηριακων μολυνσεων | |
AR123996A2 (es) | Compuestos tricíclicos novedosos como agentes antineoplásicos | |
CY1121701T1 (el) | Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων | |
CY1121120T1 (el) | Αρυλ- ή ετεροαρυλ-υποκατεστημενες ενωσεις βενζολιου | |
CY1119058T1 (el) | Ενωσεις ιμιδαζοπυρρολιδινονης | |
BR112014022214A2 (pt) | fenólicos antibacterianos | |
CY1123189T1 (el) | Αντιμικροβiακο πεπτιδιο | |
CY1119167T1 (el) | Αναστολεις toy nkcc για τη θεραπεια του αυτισμου | |
BR112014004704A2 (pt) | compostos antibacterianos e métodos de uso | |
CY1118869T1 (el) | Παραγωγα αμιδο σπειροκυκλικου αμιδιου και σουλφοναμιδιου | |
BR112014004832A2 (pt) | compostos antibacterianos e métodos para uso | |
BR112015027704A2 (pt) | Composto, uso do mesmo e composição farmacêutica antibacteriana | |
BR112015012351A2 (pt) | formulações de vancomicina estabilizadas | |
BR112013029692A2 (pt) | derivados de imidazol úteis para o tratamento da artrite | |
BR112014000665A2 (pt) | composto, uso do mesmo, composição farmacêutica, agente antimicrobiano, e, método para previnir ou tratar uma infecção bacteriana | |
BR112014021498A2 (pt) | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado | |
BR112017010132A2 (pt) | terapia combinada para tratamento de infecções bacterianas resistentes | |
CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
BR112017011478A2 (pt) | composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante | |
BR112014031866A2 (pt) | Composição farmacêutica intramamária para utilização no tratamento ou prevenção da mastite em um mamífero não humano e composição farmacêutica de fosfomicina e de pelo menos um anti-microbiano | |
RU2014149351A (ru) | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий | |
BR112016005271A2 (pt) | Moduladores de canais de sódio para o tratamento da dor e do diabetes | |
BR112014026058A2 (pt) | composições para tratamento tópico de infecções microbianas | |
BR112012005957A2 (pt) | compostos tricíclicos e usos farmacêuticos dos mesmos | |
BRPI1010948A2 (pt) | Composição compreendendo pelo menos trans- cinamaldeído e a respectiva utilização no tratamento das infecções bacterianas, mais particularmente no tratamento das doenças nosocomiais. |